Introduction
Significant questions are pending for pharmaceutical and biotech patent holders. Can human cells or genes be patented? How is public policy on this matter developing around the world? How will changes to the US patent system affect the bio-pharma industry? How will the situation regarding SPCs for biotech patents develop? What will be the impact of the EPO’s increasingly restrictive approach to biotech and pharmaceutical patents?
This conference will address these key questions, and more. Ablynx will share thoughts on best practice and Abbott Healthcare Products B. V. will comment on judicial approaches. The latest pharma and biotech case law from around the world will be analysed. It is vital that all with an interest in the effective protection of biotech and pharmaceutical patents should join us to discuss this highly topical, commercial area.
Event details
Date:
Wednesday 30 November 2011
Location:
Hyatt Regency Churchill Hotel
London, W1A 4ZX
Book by 21 October 2011 and save £50 off the full price! 30% discount for AIPPI and CIPA members
5.25
CPD
Hours
